Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Via InvestorPlace

Is Beam Therapeutics Stock a Buy Now? ↗

November 18, 2023

It has plenty of money, but it'll be facing plenty of competition, too.

Beam Therapeutics' pipeline will look slimmer going forward.

Beam Therapeutics: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? ↗

October 25, 2023

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Thursday.

What's Going On With Beam Therapeutics Stock Thursday? ↗

October 19, 2023

Via Benzinga

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks ↗

November 14, 2023

You might not get a better chance to invest in these disruptive companies.

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 08, 2023

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

November 08, 2023

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗

November 01, 2023

Via InvestorPlace

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today ↗

October 31, 2023

Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.

Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs.

Verve Stock Soars On $250 Million Eli Lilly Deal ↗

October 31, 2023

Via Investor's Business Daily

Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday ↗

October 31, 2023

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 31, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...

Via Benzinga

Topics Intellectual Property

After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? ↗

October 31, 2023

Some of the strategic shifts proposed by management are for the better.

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's

Why Beam Therapeutics Stock Is Getting Bought Today ↗

October 31, 2023

Via Benzinga

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026

Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender ↗

October 30, 2023

Via Benzinga

Topics Earnings

5 Reasons Beam Therapeutics Remains a Risky Stock ↗

October 30, 2023

Shares of the gene-editing biotech might not have hit rock bottom yet.

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

October 25, 2023

Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

October 23, 2023

U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Beam Therapeutics Stock: Bear vs. Bull ↗

October 21, 2023

This biotech has a few factors in its corner, but it also faces a difficult path.

Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell.

Investors Unpack Home Sales Data Ahead Of Fed Speech ↗

October 19, 2023

Via Talk Markets

Topics Economy

Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 19, 2023

Gainers

Via Benzinga

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

October 19, 2023